Portola Pharmaceuticals Inc (NASDAQ:PTLA) VP Mardi Dier sold 10,235 shares of the business’s stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $40.02, for a total value of $409,604.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) opened at 40.42 on Tuesday. The company’s market cap is $2.29 billion. The company’s 50-day moving average price is $33.16 and its 200 day moving average price is $24.14. Portola Pharmaceuticals Inc has a 12-month low of $15.68 and a 12-month high of $41.27.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.12) by $0.17. Portola Pharmaceuticals had a negative return on equity of 82.19% and a negative net margin of 1,072.67%. The firm earned $13.70 million during the quarter, compared to the consensus estimate of $3.98 million. During the same period last year, the business posted ($1.23) EPS. The business’s revenue was up 211.4% compared to the same quarter last year. Equities analysts predict that Portola Pharmaceuticals Inc will post ($3.56) earnings per share for the current year.
Your IP Address:
A number of hedge funds have recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Portola Pharmaceuticals during the fourth quarter worth $10,046,000. Putnam Investments LLC increased its stake in shares of Portola Pharmaceuticals by 3.0% in the fourth quarter. Putnam Investments LLC now owns 10,531 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 310 shares during the last quarter. Ellington Management Group LLC acquired a new stake in shares of Portola Pharmaceuticals during the fourth quarter worth $357,000. Orbimed Advisors LLC increased its stake in shares of Portola Pharmaceuticals by 48.7% in the fourth quarter. Orbimed Advisors LLC now owns 551,500 shares of the biopharmaceutical company’s stock worth $12,376,000 after buying an additional 180,600 shares during the last quarter. Finally, Pacad Investment Ltd. acquired a new stake in shares of Portola Pharmaceuticals during the fourth quarter worth $550,000. Hedge funds and other institutional investors own 87.38% of the company’s stock.
Several analysts recently issued reports on the company. Oppenheimer Holdings Inc. set a $28.00 target price on Portola Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, February 8th. Vetr lowered Portola Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $45.18 target price on the stock. in a report on Monday. Cowen and Company set a $40.00 target price on Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, February 8th. Credit Suisse Group AG upped their target price on Portola Pharmaceuticals from $20.00 to $29.00 and gave the stock an “outperform” rating in a report on Tuesday, December 27th. Finally, Zacks Investment Research upgraded Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a report on Wednesday, January 11th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $37.65.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.